ERBB2 and non-small cell lung carcinoma: Additionally, in February 2024, the FDA granted breakthrough therapy designation to BAY 2927088 for the treatment of adult patients with unresectable or metastatic NSCLC whose tumors have activating HER2 mutations and who have received prior systemic therapy (70).